Refarmed Chemicals takes pride in providing the pharmaceutical industry with high-quality Ticlopidine Hydrochloride, an essential antiplatelet medication used to prevent strokes and other significant blood clots in patients who have experienced a stroke or transient ischemic attack (TIA). Manufactured under stringent GMP certification, our Ticlopidine Hydrochloride is presented in tablet form, with a strength of 250 mg ensuring consistent dosing and efficacy. Our Ticlopidine Hydrochloride acts by hindering platelet function, thereby diminishing the aggregation essential to blood clot formation. This preventive approach serves as a critical intervention in the management of clot-related disorders, significantly improving patient outcomes. Physicians typically recommend a starting dose of 250 mg administered twice daily, emphasizing that food intake during administration reduces gastrointestinal discomfort. Monitoring patient response allows for personalized treatment adjustments to optimize therapeutic benefits while considering safety profiles. As with all pharmaceuticals, we duly note possible side effects, ranging from mild gastrointestinal issues to less common, yet more severe reactions like neutropenia or liver impairment. This necessitates caution in prescribing to populations with liver disease, a history of bleeding disorders, or inflammatory bowel disease. Continuous patient monitoring and drug interaction vigilance are paramount, especially concerning commonly used medications such as aspirin and warfarin. Compliant storage conditions entail keeping the Ticlopidine Hydrochloride tablets at room temperature (15°C to 30°C), shielded from light and moisture to maintain product integrity. Ticlopidine Hydrochloride is supplied as a generic medication, ensuring affordability without compromising quality. Embracing our commitment to patient safety and treatment adherence, we underline the significance of medical guidance before initiating or discontinuing use, with particular respect to special populations like pregnant or breastfeeding women. Rest assured, our partnership with the DKSH Group underlines a shared vision for growth and delivery of quality healthcare solutions that spans across Asia and beyond, cementing our position as a trusted supplier in the pharmaceutical landscape.

Products still subject to third-party patent protection might be available solely for R&D purposes.

Tulobuterol base is a high-grade bronchodilator, primarily used for managing respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). This potent pharmaceutical ingredient is engineered to target and activate beta-2 adrenoreceptors in the airways, resulting in the relaxation of bronchial smooth muscles and effective bronchodilation. Refarmed Chemicals, a key player in the pharmaceutical industry and now part of the DKSH Group, manufactures Tulobuterol base with a commitment to excellence, as evidenced by compliance with EU GMP certifications and stringent quality controls. The product is presented as a white crystalline powder, with its consistency and purity validated by a comprehensive series of tests including IR, HPLC, and TLC tests. At the onset of use, Tulobuterol base exhibits rapid action within 5-15 minutes and sustains its therapeutic effect for up to 6 hours. Its main application is for the relief and prevention of bronchospasm in patients, thereby improving airway obstruction and lung function. Administered via an aerosol inhaler or nebulizer, dosage and frequency are tailored to individual patient needs and disease severity. The product's reliability is reinforced by its exhaustive assay, showing a 98.5% - 102% active ingredient range, with controlled levels of impurities and residual solvents. Safety is a core aspect of Tulobuterol base's design, having been tested for adverse components. Common side effects may include tachycardia and nervousness, among others. Caution is advised for patients with cardiovascular disease, hypertension, and diabetes. Tulobuterol base is contraindicated for individuals with hypersensitivity to beta-adrenergic agonists, those with thyrotoxicosis or tachyarrhythmias, and it is not recommended for use in children under 12 years of age. As with all medications, potential drug interactions need to be considered, notably with beta-blockers and other beta-adrenergic agonists. This product serves as a testament to Refarmed Chemicals' dedication to providing superior pharmaceutical materials. Through their integration with DKSH, they strive to deliver growth in Asia and beyond, ensuring the availability of quality medical compounds to healthcare providers and patients worldwide.

Products still subject to third-party patent protection might be available solely for R&D purposes.